Pharmacology of LY315920/S-5920, [[3-(aminooxoacetyl)-2-ethyl-1- (phenylmethyl)-1H-indol-4-yl]oxy] acetate, a potent and selective secretory phospholipase A2 inhibitor: A new class of anti-inflammatory drugs, SPI
| Autor: | D W, Snyder, N J, Bach, R D, Dillard, S E, Draheim, D G, Carlson, N, Fox, N W, Roehm, C T, Armstrong, C H, Chang, L W, Hartley, L M, Johnson, C R, Roman, A C, Smith, M, Song, J H, Fleisch |
|---|---|
| Rok vydání: | 1999 |
| Předmět: |
Male
Arachidonic Acid Indoles Mesocricetus Anti-Inflammatory Agents Non-Steroidal Guinea Pigs Mice Transgenic Muscle Smooth Acetates Group II Phospholipases A2 Keto Acids Phospholipases A Recombinant Proteins Cell Line Rats Mice Phospholipases A2 Thromboxane A2 Cricetinae Animals Humans Pleura Rabbits Cloning Molecular |
| Zdroj: | The Journal of pharmacology and experimental therapeutics. 288(3) |
| ISSN: | 0022-3565 |
| Popis: | LY315920 is a potent, selective inhibitor of recombinant human, group IIA, nonpancreatic secretory PLA2 (sPLA2). In a chromogenic isolated enzyme assay, LY315920 inhibited sPLA2 activity with an IC50 of 9 +/- 1 nM or 7.3 x 10(-6) mole fraction, which approached the stiochiometric limit of this assay. The true potency of LY315920 was defined using a deoxycholate/phosphatidylcholine assay with a mole fraction of 1.5 x 10(-6). LY315920 was 40-fold less active against human, group IB, pancreatic sPLA2 and was inactive against cytosolic PLA2 and the constitutive and inducible forms of cyclooxygenase. Human sPLA2-induced release of thromboxane A2 (TXA2) from isolated guinea pig lung bronchoalveolar lavage cells was inhibited by LY315920 with an IC50 of 0.79 microM. The release of TXA2 from these cells by N-formyl-methionyl-leucyl-phenylalanine or arachidonic acid was not inhibited. The i.v. administration of LY315920, 5 min before harvesting the bronchoalveolar lavage cells, resulted in the inhibition of sPLA2-induced production of TXA2 with an ED50 of 16.1 mg/kg. Challenge of guinea pig lung pleural strips with sPLA2 produced contractile responses that were suppressed in a concentration-dependent manner by LY315920 with an apparent KB of 83 +/- 14 nM. Contractile responses induced by arachidonic acid were not altered. Intravenous or oral administration of LY315920 to transgenic mice expressing the human sPLA2 protein inhibited serum sPLA2 activity in a dose-related manner over a 4-h time course. LY315920 is a potent and selective sPLA2 inhibitor and represents a new class of anti-inflammatory agent designated SPI. This agent is currently undergoing clinical evaluation and should help to define the role of sPLA2 in various inflammatory disease states. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|